ReviewNature reviews. Nephrology2013
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Review in Nature reviews. Nephrology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 34 citations in OpenAlex.
- Unveiling the Therapeutic Potential of Suyin Detoxification Prescription in Diabetic Nephropathy: A Comprehensive Study Integrating Clinical Efficacy, Network Pharmacology, and Molecular Mechanisms.Journal of diabetes research · 2025Trial
- Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment.Clinical drug investigation · 2014Trial
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.Diabetes, obesity & metabolism · 2013 · on this mapTrial
- Accuracy of Dexcom G6 Pro and G7 Continuous Glucose Monitors in Patients Treated with Maintenance Dialysis.Diabetes technology & therapeutics · 2026Article
- Glycemic Management and Individualized Diabetes Care in Dialysis-Dependent Kidney Failure.Diabetes care · 2025Review
- 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023.Diabetes care · 2023Review
- In Situ Regulation of Macrophage Polarization to Enhance Osseointegration Under Diabetic Conditions Using Injectable Silk/Sitagliptin Gel Scaffolds.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Clinical Significance of Serum lncRNA Cancer Susceptibility Candidate 2 (CASC2) for Chronic Renal Failure in Patients with Type 2 Diabetes.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Review
- Article
- Prescribing for patients on dialysis.Australian prescriber · 2016Review
- Haemodialysis-induced hypoglycaemia and glycaemic disarrays.Nature reviews. Nephrology · 2015Review
- The clinical application of linagliptin in Asians.Therapeutics and clinical risk management · 2015Review
- Updates on the management of diabetes in dialysis patients.Seminars in dialysis · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is a common complication of diabetes mellitus and the most common cause of end-stage renal disease (ESRD). As the worldwide prevalence of diabetes continues to increase, the number of patients with CKD will also increase. Therefore, it is essential that physicians know how to safely and effectively manage diabetes in the setting of CKD. Adequate glycaemic control in patients with diabetes is important to prevent ESRD and other complications and to decrease mortality. However, many glucose-lowering agents need to be dose-adjusted or should not be used in the setting of stage 3 CKD or higher (defined as an estimated glomerular filtration rate [eGFR] <60 ml/min/1.73 m(2)), particularly in patients with stage 5 CKD (eGFR <15 ml/min/1.73 m(2)) and in those receiving dialysis. Insulin therapy is appropriate for patients undergoing dialysis; however, several orally administered glucose-lowering agents can also be used safely in these patients. In this Review, we provide an overview of the use of noninsulin glucose-lowering agents in the dialysis population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.